TRK 380

Drug Profile

TRK 380

Alternative Names: Beta-3 adrenoceptor agonist - Toray/Taiho; TAC-301; TRK-380

Latest Information Update: 06 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toray
  • Class
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 06 Apr 2016 No recent reports on development identified - Phase-I for Overactive bladder in Japan (Unspecified)
  • 30 Mar 2012 Taiho Pharmaceuticals and Toray terminate their agreement to co-develop and commercialise TRK 380 for Overactive bladder in Japan
  • 01 Jan 2011 Phase-I clinical trials in Overactive bladder in Japan (Unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top